We demonstrate that pre-treatment with anti-CTLA4 antibodies provided optimal tumor control, while an alternate immunotherapy with anti-OX40, which targets recently-activated T cells, was optimal if delivered immediately following radiation therapy. This evidence concerns the gene CTLA4 and neoplasm.